Emergent BioSolutions Gets Anthrax Vaccine Contract Modification Up to $22.3M
By Elias Schisgall
Emergent BioSolutions received a contract modification valued at up to $22.3 million to supply its BioThrax vaccine to the Defense Department.
The company said the modification, which exercises an option period under its existing contract with the Pentagon, includes an initial delivery valued around $7.4 million set to take place this year. Remaining deliveries are expected to occur next year.
"We're pleased to continue supporting the Department of War's efforts to maintain preparedness against critical biological threats like anthrax," the company's head of products business, global government and public affairs, Paul Williams, said Wednesday. "Delivering dependable access to BioThrax helps protect our nation's service members who have an elevated risk of anthrax exposure."
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
November 04, 2026 17:59 ET (22:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
The 10 Best Companies to Invest in Now
This Once-Hot AI Stock Now Looks Deeply Undervalued
United States